Abstract:Intrinsically disordered proteins (IDPs) lack a well-defined tertiary structure but are essential players in various biological processes. Their ability to undergo a disorder-to-order transition upon binding to their partners, known as the folding-upon-binding process, is crucial for their function. One classical example is the intrinsically disordered transactivation domain (TAD) of the tumor suppressor protein p53, which quickly forms a structured alpha-helix after binding to its partner MDM2, with clinical significance for cancer treatment. However, the contribution of nonnative interactions between the IDP and its partner to the rapid binding kinetics, as well as their interplay with native interactions, is not well understood at the atomic level. Here, we used molecular dynamics simulation and Markov state model (MSM) analysis to study the folding-upon-binding mechanism between p53-TAD and MDM2. Our results suggest that the system progresses from the nascent encounter complex to the well-structured encounter complex and finally reaches the native complex, following an induced-fit mechanism. We found that nonnative hydrophobic and hydrogen bond interactions, combined with native interactions, effectively stabilize the nascent and well-structured encounter complexes. Among the nonnative interactions, Leu25(p53)-Leu54(MDM2) and Leu25(p53)-Phe55(MDM2) are particularly noteworthy, as their interaction strength is close to the optimum. Evidently, strengthening or weakening these interactions could both adversely affect the binding kinetics. Overall, our findings suggest that nonnative interactions are evolutionarily optimized to accelerate the binding kinetics of IDPs in conjunction with native interactions.

Chemical induction of the interaction between AIMP2-DX2 and Siah1 to enhance ubiquitination

Bi-directional regulation of AIMP2 and its splice variant on PARP-1-dependent neuronal cell death; Therapeutic implication for Parkinson's disease

Characterizing the protein–protein interaction between MDM2 and 14-3-3σ; proof of concept for small molecule stabilization

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Small Molecule Inhibitors of the P53-Mdm2

Effect of Substituents in Different Positions of Aminothiazole Hinge-Binding Scaffolds on Inhibitor–CDK2 Association Probed by Interaction Entropy Method

Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue.

Inhibition of Syk Promotes Chemical Reprogramming of Fibroblasts Via Metabolic Rewiring and H2 S Production.

Data from Oncogenic Mutation of AIMP2/p38 Inhibits Its Tumor-Suppressive Interaction with Smurf2

Oncogenic Mutation of AIMP 2 / P 38 Inhibits Its Tumor-Suppressive Interaction with Smurf 2

Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction

Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer

Α-Helix-mimicking Sulfono-γ-AApeptide Inhibitors for P53–mdm2/mdmx Protein–Protein Interactions

Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors

Chemical interference with DSIF complex formation lowers synthesis of mutant huntingtin gene products and curtails mutant phenotypes

A computational analysis of interaction mechanisms of peptide and non-peptide inhibitors with MDMX based on molecular dynamics simulation

Impact of Nonnative Interactions on the Binding Kinetics of Intrinsically Disordered P53 with MDM2: Insights from All-Atom Simulation and Markov State Model Analysis.

Insight into Interaction Mechanism of the Inhibitor Pdi6w with MDM2 Based on Molecular Dynamics

Supplementary Figure S5 from Oncogenic Mutation of AIMP2/p38 Inhibits Its Tumor-Suppressive Interaction with Smurf2

Computational-based drug design of novel small molecules targeting p53-MDMX interaction

An Ultrahigh Affinity D-Peptide Antagonist of MDM2.